Patents Examined by Jennifer Dunston
  • Patent number: 9708670
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: July 18, 2017
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 9708669
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: July 18, 2017
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 9708668
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: July 18, 2017
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 9695396
    Abstract: A normal regenerated tissue is formed by exposing to radiation a connective tissue or a supporting tissue originating in an organ to thereby form a feeder layer and then transplanting epithelial cells thereon to form a stratified structure. By conveniently and surely providing regenerated tissue by the 3-dimensional culture with the use of a human-origin normal tissue as a base, it is possible to construct systems for assessing effects and side effects of chemicals such as drugs or assessing sensitivities thereof with the use of regenerated tissues as models of corresponding tissues respectively.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: July 4, 2017
    Assignee: SHIGEKAZU NAKATSUGAWA
    Inventor: Shigekazu Nakatsugawa
  • Patent number: 9695442
    Abstract: Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: July 4, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Dmitry Guschin, Fyodor Urnov
  • Patent number: 9682123
    Abstract: The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 20, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Rudolph L. Leibel, Kazuhisa Watanabe, Wendy K. Chung, Stuart G. Fischer, Charles Leduc, Elizabeth Watson, Maria Laura Cremona
  • Patent number: 9629927
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: April 25, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • Patent number: 9580756
    Abstract: Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Steven Buechler, Amanda B. Hummon
  • Patent number: 9574226
    Abstract: Provided herein is a method of using transposition to improve methods of sequencing RNA molecules. Provided herein is a method of tagging nucleic acid duplexes, such as DNA:RNA duplexes or DNA:DNA duplexes. The method includes the steps of providing a transposase and a transposon composition, providing one or more nucleic acid duplexes immobilized on a support, and contacting the transposase and transposon composition with the one or more nucleic acid duplexes under conditions wherein the one or more nucleic acid duplexes and transposon composition undergo a transposition reaction to produce one or more tagged nucleic acid duplexes, wherein the transposon composition comprises a double stranded nucleic acid molecule comprising a transferred strand and a non-transferred strand.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 21, 2017
    Assignee: Illumina, Inc.
    Inventors: Niall Anthony Gormley, Louise Fraser, Paula Kokko-Gonzales
  • Patent number: 9567608
    Abstract: The present invention relates to genetic techniques employing the direct ligatation of an external DNA fragment generated in situ by the same ZFNs that target the genome. ObLiGaRe, i.e., the obligated ligation-gated recombination, is a new method for genetic engineering using custom designed nucleases, and a strategy of site-specific gene insertion utilizing the NHEJ pathway. It applies a similar logic to the one used in unidirectional loxP sites (Oberdoerffer et al., 2003) but maintains all the advantages and flexibility of CDNs.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 14, 2017
    Assignee: Novartis AG
    Inventors: Yi Yang, Marcello Maresca
  • Patent number: 9546369
    Abstract: Some aspects of this invention provide nucleic acid constructs for transgene expression. Some aspects of this invention provide multicistronic nucleic acid constructs, for example, comprising an expression cassette encoding a hairpin RNA and a reporter expression cassette. Some aspects of this invention provide nucleic acid constructs comprising two or more self-complementary nucleic acid sequences, for example, hairpin RNA encoding nucleic acid sequences and AAV inverse terminal repeats. Methods for the use of the constructs in therapy and research are also provided.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: January 17, 2017
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Jun Xie
  • Patent number: 9540623
    Abstract: The present invention relates to a method for increasing double-strand-break induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. More specifically, the present invention concerns the combined use of TALEN or meganucleases with TREX2, especially under the form of single-chain proteins.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: January 10, 2017
    Assignee: CELLECTIS
    Inventors: George H. Silva, Rachel Macmaster
  • Patent number: 9534248
    Abstract: The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: January 3, 2017
    Inventors: Sanjiv S. Gambhir, John A. Ronald
  • Patent number: 9523101
    Abstract: Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 20, 2016
    Assignee: The Catholic University of America
    Inventor: Venigalla B. Rao
  • Patent number: 9523674
    Abstract: The object of the present invention is to provide a method for screening a substance capable of promoting induction of induced pluripotent stem cells from cells derived from an individual affected by a disease for which it is impossible to produce induced pluripotent stem cells simply by introducing reprogramming genes. The present invention provides a method for screening a substance, which comprises culturing cells derived from an individual affected by a disease for which it is impossible to produce induced pluripotent stem cells simply by introducing reprogramming genes, the cells being transfected with reprogramming genes, in the presence of test substances, and selecting a test substance capable of promoting induction of induced pluripotent stem cells from the cells.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: December 20, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventor: Takumi Era
  • Patent number: 9517258
    Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 13, 2016
    Assignees: Mayo Foundation for Medical Education and Research, University of Leeds
    Inventors: Jose S. Pulido, Richard G. Vile, Timothy J. Kottke, Alan A. Melcher, Peter Selby
  • Patent number: 9512489
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 6, 2016
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 9512444
    Abstract: The present invention provides methods and kits for editing specific chromosomal sequences in cells. In particular, targeting endonucleases and single-stranded nucleic acids are used to edit the chromosomal sequence.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: December 6, 2016
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Fuqiang Chen, Shondra M. Pruett-Miller, Gregory D. Davis
  • Patent number: 9506073
    Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 29, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kevin H. Gardner, Laura B. Motta-Mena, Brian D. Zoltowski
  • Patent number: 9506120
    Abstract: Disclosed herein are methods and compositions for rapidly identifying and ranking nucleases for specific cleavage of a target sequence.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: November 29, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Yannick Doyon, Fyodor Urnov